DGM
SWTX

Darwin Global Management’s SpringWorks Therapeutics SWTX Stock Holding History

Darwin Global Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-192,734
Closed -$7.03M – 15
2023
Q4 		$7.03M Buy
+192,734
New +$5.03M 1.38% 7

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Darwin Global Management's SWTX Position: Q1 2024 in Review

Darwin Global Management sold out of SpringWorks Therapeutics (SWTX) in Q1 2024, closing a stake of 192,734 shares — an estimated $7.03M sold.

Darwin Global Management first reported a position in SWTX in Q4 2023 and held it in 1 quarter. The position peaked at $7.03M in Q4 2023. 217 funds tracked by Wall St. Rank hold SWTX as of Q1 2024.

  • Darwin Global Management reported no remaining SpringWorks Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Darwin Global Management sold 192,734 SpringWorks Therapeutics shares in Q1 2024, an estimated $7.03M.
  • Darwin Global Management first reported a position in SpringWorks Therapeutics in Q4 2023 and held it in 1 quarter.
  • Darwin Global Management's SpringWorks Therapeutics position peaked at $7.03M in Q4 2023.
  • 217 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2024.

Based on Darwin Global Management's 13F filing for Q1 2024, filed 15 May 2024.